U.S. Markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.22
    -0.21 (-0.19%)
     
  • Gold

    1,812.10
    +10.60 (+0.59%)
     
  • Silver

    19.78
    +0.19 (+0.96%)
     
  • EUR/USD

    1.0431
    +0.0004 (+0.0417%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2094
    -0.0009 (-0.0762%)
     
  • USD/JPY

    135.1280
    -0.0470 (-0.0348%)
     
  • BTC-USD

    19,128.35
    -152.08 (-0.79%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    26,067.22
    +131.60 (+0.51%)
     

Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Altimmune, Inc
Altimmune, Inc

GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on May 12 to discuss financial results and provide a business update.

Conference Call Information:

Date:

Thursday, May 12

Time:

8:30 am Eastern Time

Domestic Dial-in:

(800) 225-9448

International Dial-in:

(203) 518-9708

Conference ID:

ALTQ122

Webcast:

https://edge.media-server.com/mmc/p/j5i9f735

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com